Full Text:
<2154>
Summary: 
<653>
Suppl. Mater.: 
CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 3633
Citations: Bibtex RefMan EndNote GB/T7714
OShnscc: a novel user-friendly online survival analysis tool for head and neck squamous cell carcinoma based on RNA expression profiles and long-term survival information
| ||||||||||||||
Guosen ZHANG, Qiang WANG, Xinlei QI, Huimin YANG, Xiaodong SU, Manman YANG, Chao JIANG, Yang AN, Hong ZHENG, Lu ZHANG, Wan ZHU, Jiancheng GUO, Xiangqian GUO. OShnscc: a novel user-friendly online survival analysis tool for head and neck squamous cell carcinoma based on RNA expression profiles and long-term survival information[J]. Journal of Zhejiang University Science B, 2022, 23(3): 249-257.
@article{title="OShnscc: a novel user-friendly online survival analysis tool for head and neck squamous cell carcinoma based on RNA expression profiles and long-term survival information",
author="Guosen ZHANG, Qiang WANG, Xinlei QI, Huimin YANG, Xiaodong SU, Manman YANG, Chao JIANG, Yang AN, Hong ZHENG, Lu ZHANG, Wan ZHU, Jiancheng GUO, Xiangqian GUO",
journal="Journal of Zhejiang University Science B",
volume="23",
number="3",
pages="249-257",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2100512"
}
%0 Journal Article
%T OShnscc: a novel user-friendly online survival analysis tool for head and neck squamous cell carcinoma based on RNA expression profiles and long-term survival information
%A Guosen ZHANG
%A Qiang WANG
%A Xinlei QI
%A Huimin YANG
%A Xiaodong SU
%A Manman YANG
%A Chao JIANG
%A Yang AN
%A Hong ZHENG
%A Lu ZHANG
%A Wan ZHU
%A Jiancheng GUO
%A Xiangqian GUO
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 3
%P 249-257
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2100512
TY - JOUR
T1 - OShnscc: a novel user-friendly online survival analysis tool for head and neck squamous cell carcinoma based on RNA expression profiles and long-term survival information
A1 - Guosen ZHANG
A1 - Qiang WANG
A1 - Xinlei QI
A1 - Huimin YANG
A1 - Xiaodong SU
A1 - Manman YANG
A1 - Chao JIANG
A1 - Yang AN
A1 - Hong ZHENG
A1 - Lu ZHANG
A1 - Wan ZHU
A1 - Jiancheng GUO
A1 - Xiangqian GUO
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 3
SP - 249
EP - 257
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2100512
Abstract: head and neck squamous cell carcinoma (HNSCC), as the most common type (>90%) of head and neck cancer, includes various epithelial malignancies that arise in the nasal cavity, oral cavity, pharynx, and larynx. In 2020, approximately 878 000 new cases and 444 000 deaths linked to HNSCC occurred worldwide (Sung et al., 2021). Due to the associated frequent recurrence and metastasis, HNSCC patients have poor prognosis with a five-year survival rate of 40%–50% (Jou and Hess, 2017). Therefore, novel prognostic biomarkers need to be developed to identify high-risk HNSCC patients and improve their disease outcomes.
[1]FauziFH, HamzanNI, RahmanNA, et al., 2020. Detection of human papillomavirus in oropharyngeal squamous cell carcinoma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(12):961-976.
[2]HanavadiS, MartinTA, WatkinsG, et al., 2006. Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann Surg Oncol, 13(6):802-808.
[3]JouA, HessJ, 2017. Epidemiology and molecular biology of head and neck cancer. Oncol Res Treat, 40(6):328-332.
[4]KimKY, McShaneLM, ConleyBA, 2014. Designing biomarker studies for head and neck cancer. Head Neck, 36(7):1069-1075.
[5]LiuJF, LichtenbergT, HoadleyKA, et al., 2018. An integrated TCGA Pan-Cancer Clinical Data Resource to drive high-quality survival outcome analytics. Cell, 173(2):400-416.e11.
[6]NaghaviAO, EchevarriaMI, StromTJ, et al., 2016. Treatment delays, race, and outcomes in head and neck cancer. Cancer Epidemiol, 45:18-25.
[7]NagyÁ, LánczkyA, MenyhártO, et al., 2018. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep, 8:9227.
[8]PaiSI, WestraWH, 2009. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol, 4:49-70.
[9]PanD, XuL, LiuHO, et al., 2015. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Cancer Sci, 106(5):592-597.
[10]PolanskaH, RaudenskaM, GumulecJ, et al., 2014. Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol, 50(3):168-177.
[11]SungH, FerlayJ, SiegelRL, et al., 2021. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3):209-249.
[12]TangZF, LiCW, KangBX, et al., 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 45(W1):W98-W102.
[13]WichmannG, RosolowskiM, KrohnK, et al., 2015. The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer, 137(12):2846-2857.
[14]XuDH, ZhuZW, WakefieldMR, et al., 2016. The role of IL-11 in immunity and cancer. Cancer Lett, 373(2):156-163.
[15]XuN, DongRN, LinTT, et al., 2021. Development and validation of novel biomarkers related to M2 macrophages infiltration by weighted gene co-expression network analysis in prostate cancer. Front Oncol, 11:634075.
[16]ZhangGS, WangQ, YangMS, et al., 2019. OSblca: a web server for investigating prognostic biomarkers of bladder cancer patients. Front Oncol, 9:466.
[17]ZhaoM, LiuY, LiuR, et al., 2018. Upregulation of IL-11, an IL-6 family cytokine, promotes tumor progression and correlates with poor prognosis in non-small cell lung cancer. Cell Physiol Biochem, 45(6):2213-2224.
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>